A novel and safe approach for treating cognitive disorders
March 14, 2022 Non RegulatoryUmecrine Cognition completes successful pre-IND meeting with FDASTOCKHOLM – March 14, 2022. Umecrine Cognition AB today announces that the company has completed a pre-IND meeting with the U.S. Food and Drug...
February 21, 2022 Non RegulatoryUmecrine Cognition to present preclinical results showing beneficial effects of golexanolone on neuroinflammation and movement dysfunctionSTOCKHOLM – February 21, 2022. Umecrine Cognition AB today announces that the company will present positive data from a recently concluded...
January 10, 2022 Non RegulatoryUmecrine Cognition presents data showing a reduction of neuroinflammation following treatment with golexanoloneStockholm, January 10, 2022 – Umecrine Cognition AB today announced nonclinical results showing that its clinical drug candidate golexanolone...
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.